Dr Ning Wang
Department of Oncology and Metabolism
+44 114 215 9216
Full contact details
Department of Oncology and Metabolism
DU10, D Floor
The Medical School
Beech Hill Road
I undertook my undergraduate (BSc) and postgraduate (MRes) training in biology at Ocean University of China. After moving to the UK in 2004, I studied the trend of Biotech-industry development at Loughborough University and gained my MSc in Management the following year.
I then joined Professor Alison Gartland’s group in Sheffield and was awarded my PhD in 2010 after completing my PhD project in investigating the roles of purinergic signalling in osteoporosis. I was subsequently appointed as a Post-doctoral Research Associate in Dr Colby Eaton’s lab and developed the models used in the identification of dormant metastasis initiating tumour cells in a Cancer Research UK programme grant.
I was then employed as a Senior Post-doctoral Research Associate in Professor Tim Skerry’s group within the Department of Oncology & Metabolism and worked on the Wellcome Trust sponsored programme in development of novel agents for the treatment of pancreatic cancer. I am currently an independent Research Fellow in the Academic Group of Bone Biology.
- Research interests
My research interests are focused on bone oncology and bone biology. My current autonomous research is to determine how exercise-induced cellular changes affect cancer bone metastasis.
I am also interested in characterizing metastasis initiating cells and investigating interactions between these cells and bone microenvironment, as continuous development of a Cancer Research UK sponsored research programme. In addition, investigating the role of purinergic signalling in other musculoskeletal diseases such as osteoporosis and osteoarthritis is also in my research interests.
- Determining the impact of mechanical loading induced bone remodelling on the initiation and progression of prostate cancer skeletal metastasis (Prostate Cancer UK Research Innovation Award)
- Determining the impact of exercise on the initiation of breast cancer skeletal metastasis using pre-clinical models (Weston Park Cancer Charity Large Grant)
- Defining the role of P2X7 receptor in the prostate cancer metastasizing into the skeleton (The Royal Society International Exchange Scheme)
- PTH(1–34) treatment and/or mechanical loading have different osteogenic effects on the trabecular and cortical bone in the ovariectomized C57BL/6 mouse. Scientific Reports, 10(1).
- Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
- Discovery of a first-in-class potent small molecule antagonist against the adrenomedullin-2 receptor. ACS Pharmacology & Translational Science. View this article in WRRO
- The longitudinal effects of ovariectomy on the morphometric, densitometric and mechanical properties in the murine tibia : a comparison between two mouse strains. Bone, 127, 260-270. View this article in WRRO
- The bone metastasis niche in breast cancer–potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology, 17. View this article in WRRO
- Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
- Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer.. International Journal of Molecular Sciences, 19(10). View this article in WRRO
- P2X7 receptor regulates osteoclast function and bone loss in a mouse model of osteoporosis. Scientific Reports, 8(1). View this article in WRRO
- The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis. Current Molecular Biology Reports, 3(3), 197-203. View this article in WRRO
- Bone turnover is altered in transgenic rats overexpressing the P2Y2 purinergic receptor. Purinergic Signalling.
- Confocal/two-photon microscopy in studying colonisation of cancer cells in bone using xenograft mouse models. BoneKEy Reports, 5, 851-851. View this article in WRRO
- Mouse models for studying prostate cancer bone metastasis. BoneKEy Reports, 5. View this article in WRRO
- The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. Journal of Experimental and Clinical Cancer Research, 34(1), 124-124. View this article in WRRO
- OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. International Journal of Cancer, 137(4), 968-977. View this article in WRRO
- Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer. The FASEB Journal, 29(8), 3141-3150. View this article in WRRO
- Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.. J Bone Miner Res, 29(12), 2688-2696. View this article in WRRO
- Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine Related Cancer, 21(5), 769-781.
- Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.. Clin Cancer Res, 20(11), 2922-2932. View this article in WRRO
- Targeting P2 receptors--current progress in treating musculoskeletal diseases.. Curr Opin Pharmacol, 16, 122-126. View this article in WRRO
- The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development.. FASEB J, 28(5), 2249-2259. View this article in WRRO
- Role of the P2Y
13receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Stem Cells, 31(12), 2747-2758. View this article in WRRO
- Role of the P2X7 receptor in the osteogenic differentiation of mesenchymal cells and in osteoclast fusion: Presented by: Maria P. Abbracchio. Purinergic Signalling, 9(3), 281-284. View this article in WRRO
- The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading.. J Bone Miner Res, 28(6), 1446-1456. View this article in WRRO
- Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model. Poster Discussion Abstracts.
- Purinergic signalling in bone.. Front Endocrinol (Lausanne), 3, 116. View this article in WRRO
- Reduced bone turnover in mice lacking the P2Y13 receptor of ADP.. Mol Endocrinol, 26(1), 142-152. View this article in WRRO
- The P2Y(6) receptor stimulates bone resorption by osteoclasts.. Endocrinology, 152(10), 3706-3716. View this article in WRRO
- [Effects of enzymatic bone powder on calcium absorption and bone density in rats].. Wei sheng yan jiu = Journal of hygiene research, 40(4), 492-494.
- Bone phenotypes of P2 receptor knockout mice. Frontiers in Bioscience(S3), 1038-1046.
- Purification and characterization of trypsin-like enzymes from North Pacific krill (Euphausia pacifica).. Biotechnol Lett, 30(1), 67-72. View this article in WRRO
- Relating trypsin enzymatic properties with amino acid composition. International Journal of Peptide Research and Therapeutics, 14(2), 81-87.
- Role of receptor activity modifying protein 3 in the response of bone to mechanical loading. Bone Abstracts.
- Role of receptor activity modifying proteins in skeletal regulation. Bone Abstracts.
- Tracking Cancer Cells Colonization in Rodent Bone Using Two-Photon Microscopy, Methods in Molecular Biology (pp. 631-639). Springer New York
Conference proceedings papers
- P2X7 receptor in prostate cancer bone metastasis initiating cells. PURINERGIC SIGNALLING, Vol. 14 (pp S13-S13)
- P2Y2 receptor overexpression results in decreased bone formation. BONE, Vol. 50 (pp S67-S67)
- P2Y2 receptor overexpression results in decreased bone formation. BONE, Vol. 50 (pp S85-S86)
- Deletion of the P2Y13 receptor leads to reduced bone turnover and protection from ovariectomy-induced bone loss. BONE, Vol. 48 (pp S227-S227)
- The role of P2X(7) receptors in ATP release from osteoblasts. PURINERG SIGNAL, Vol. 6(1) (pp 129-129)
- The Effect of ATP on cancer cell proliferation in vitro -involvement of multiple P2X Receptors. PURINERG SIGNAL, Vol. 6(1) (pp 140-140)
- Bone Phenotype of P2Y13 Receptor Knock-Out Mice. PURINERG SIGNAL, Vol. 6(1) (pp 144-144)
- Mice Lacking NMDA Receptor Expression in Osteoblasts Have Pronounced Vertebral Bone Abnormalities. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S87-S87)
- Different types of mechanical loading induce differentitial ATP release from osteoblasts grown on 3-dimensional scaffolds. PURINERG SIGNAL, Vol. 4 (pp S164-S165)
- The effect of ATP, alone and in combination with EGF, on breast cancer cell survival. PURINERG SIGNAL, Vol. 4 (pp S205-S206)
- Research group
- Hector M Arredondo
- Jiepei He
- Teaching interests
My teaching interests are mainly supervising research projects for both postgraduates (PhD and MSc) and undergraduate (BMedSci and SSC). I also teach cancer and bone biology related lectures on the MSc in Human Nutrition, MSc in Molecular Medicine, and the CIMA MRes Musculoskeletal Ageing.
- Professional activities
I regularly review research articles for a number of international journals such as Scientific Reports, PlosOne, Anti-Cancer Drugs, and Journal of Bone Oncology, as well as grant applications for external funding bodies.